All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MPN Hub spoke with Olatoyosi Sobulo Odenike, The University of Chicago, Chicago, US. We asked, What are the key considerations in the management of MPN in accelerated phase (MPN-AP)?
What are the key considerations in the management of MPN-AP?
Odenike discusses MPN-AP, she mentions allogeneic stem cell transplants and challenges such as short survival rates in patients.
Survival outcomes following allo-HSCT in patients with accelerated phase myelofibrosis
Allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only curative option for myelofibrosis (MF).
How did newer prognostic models change treatment algorithms in primary and secondary MF?
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MPN Hub spoke with Laura Michaelis, Medical College of Wisconsin, Milkwaukee, US. We...
Subscribe to get the best content related to MPN delivered to your inbox